A Phase I clinical trial of the anti-GPC3 monoclonal antibody Codrituzumab combined with atezozumab showed that the agents were well-tolerated and effective in reducing tumor growth in patients with advanced HCC. The gene discussed is GPC3; the disease is neoplasm.